Advertisement

eRelevance Uncovers Marketing Truths, EADV Data, Primetime for Botox
eRelevance Uncovers Marketing Truths, EADV Data, Primetime for Botox

eRelevance Uncovers Marketing Truths, EADV Data, Primetime for Botox

The State of Aesthetic Healthcare Marketing 2017 from eRelevance shows that nearly 60 percent of aesthetic physicians say they either don't see results from their marketing initiatives or aren't able to measure results. Data presented at the annual meeting of the European Academy of Dermatology and Venereology support the role of Regeneron and Sanofi's Dupixent, Lilly's experimental JAK inhibitor Baricitinib, Novartis' Cosentyx, Janssen's Tremfya, and a new low-level blue and red light therapy face mask for acne vulgaris. Athlete and sports analyst Deion Sanders recently turned 50, and he's talking about the Botox Cosmetic treatment he received for the milestone.

Advertisement